Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Dose-Escalation of HL237 in Healthy Males
NCT03278470Phase 1Completed
- Sponsor
- Hanlim Pharm
- Start
- Jun 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HL237 in rheumatoid arthritis (RA) (7 arms), sponsored by Hanlim Pharm. Primary endpoints: Maximum Plasma Concentration at 3 days, Area Under the Curve at 3 days and 1 more. Started Jun 2017; status: completed.
02
Drugs
HL237
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03278470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03278470.